Atezolizumab-MMAE

Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. It consists of a humanized anti-PD-L1 antibody (Atezolizumab), a lysosome-cleavable dipeptide linker (valine-citrulline), and a tubulin inhibitor (MMAE), with the drug-linker conjugate being VcMMAE. This ADC exhibits potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effects. In the MC38 xenograft humanized PD-1 immune system mouse model, Atezolizumab-MMAE demonstrates significant antitumor activity.